ProPhase anticipates significant sequential improvement in revenues and EBITDA in Q4 2024, and beyond, driven by strategic advancements across its subsidiaries. The company remains financially strong, with $3.1 million in cash and cash equivalents as of November 12, 2024, and an improved working capital position from the quarter end.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PRPH:
- ProPhase Labs files $291.61M mixed securities shelf
- ProPhase Labs 4.17M share Spot Secondary priced at $.72
- ProPhase Labs announces common stock offering, no amount given
- PRPH Earnings this Week: How Will it Perform?
- ProPhase Labs launches DNA Complete, a direct-to-consumer DNA test
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
